Xynomic Pharmaceuticals Holdings, Inc. Common Stock
XYN
XYN was delisted on the 16th of July, 2019.
4 hedge funds and large institutions have $107K invested in Xynomic Pharmaceuticals Holdings, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.07% more ownership
Funds ownership: 0% → 0.07% (+0.07%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$32.5K |
| 2 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
+$32.5K |
| 3 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$32.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.41K |
Top Sellers
XYN Hedge Fund Activity: Q2 2019 in Review
4 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Xynomic Pharmaceuticals Holdings, Inc. Common Stock (XYN) for Q2 2019, worth a combined $107K.
Buyers outnumbered sellers: 4 funds opened new XYN positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $32.5K.
- 4 institutional investors held Xynomic Pharmaceuticals Holdings, Inc. Common Stock (XYN) as of Q2 2019, up from 0 in Q1 2019.
- Funds reported $107K of Xynomic Pharmaceuticals Holdings, Inc. Common Stock stock for Q2 2019.
- 4 funds opened new Xynomic Pharmaceuticals Holdings, Inc. Common Stock positions in Q2 2019 and 0 closed out, a net change of +4 holders.
- The largest Xynomic Pharmaceuticals Holdings, Inc. Common Stock buyer in Q2 2019 was 683 Capital Management, an estimated $32.5K added.
Based on aggregated 13F filings for Q2 2019.